Novel Oral Agent for ESR1-Mutated Breast Cancer Boosts PFS in Second-Line

(MedPage Today) -- CHICAGO -- The investigational oral agent vepdegestrant more than doubled median progression-free survival (PFS) versus fulvestrant (Faslodex) in previously treated estrogen receptor (ER)-positive metastatic breast cancer patients...